The aim of this study is to evaluate the complete remission rates, endoscopic relapses, study discontinuation rates, and quality of life parameters in patients with erosive GERD. The study duration consists of a treatment period up to 16 weeks according to the classical healing concept or the complete remission concept. During this period, the patients will receive pantoprazole (tablet) at one dose level once daily. The following observational phase lasts up to 6 months. The study will provide further data on efficacy, safety, and tolerability of pantoprazole.

Main Inclusion Criteria:

• Written informed consent
• Endoscopically confirmed GERD (Los Angeles classification A-D)
• Patients whose compliance is expected to be high with respect to the completion of the questionnaires

Main Exclusion Criteria:

• Other gastrointestinal diseases
• Severe concomitant diseases
• Proton pump inhibitors (PPIs) during last 14 days before start
• H2 receptor antagonists, prokinetics during last 7 days before study start
• Helicobacter pylori (H. pylori) eradication during last 28 days before study start